Get the Stockscreener App
36.99
2.63%
-1.00
After Hours:
36.99
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
JMP Securities Reaffirms "Market Outperform" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $56.00 - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price - MarketBeat
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
(PTGX) Investment Analysis - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 5.6%Time to Buy? - MarketBeat
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Pacer Advisors Inc. Acquires 142,376 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Inspire Investing LLC - MarketBeat
Protagonist Therapeutics to Participate in Upcoming Investor Conferences - ACCESS Newswire
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress - ACCESS Newswire
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - ACCESS Newswire
Market Recap Check: Protagonist Therapeutics Inc (PTGX)’s Positive Finish at 37.80, Up/Down 2.49 - The Dwinnex
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - ACCESS Newswire
52,239 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Assenagon Asset Management S.A. - MarketBeat
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Protagonist Therapeutics chief medical officer sells shares for tax obligations - Investing.com India
Protagonist Therapeutics chief medical officer sells shares for tax obligations By Investing.com - Investing.com Australia
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $53.78 - Defense World
Protagonist Therapeutics CFO Ali Asif reports stock sale By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 6.2%Time to Sell? - MarketBeat
Long Term Trading Analysis for (PTGX) - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% HigherStill a Buy? - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $53.78 Consensus PT from Brokerages - MarketBeat
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics announces executive role change By Investing.com - Investing.com Australia
Protagonist Therapeutics announces executive role change - Investing.com
Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Officer, Grants Equity Awards - StockTitan
Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4%What's Next? - MarketBeat
Principal Financial Group Inc. Acquires 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Principal Financial Group Inc. Purchases 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):